TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8511727

Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate (BDP), 750 micrograms twice daily
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate (BDP), 1500 micrograms twice daily
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Oral prednisolone, 40 mg per day
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate (BDP)
Number of subjects: 105
Study: 3493852

Group type: EXPERIMENTAL
Intervention: Propofol (2.5 mg X kg‐1)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Thiopentone (4 mg X kg‐1)
Number of subjects: 90
Study: 29219638

Group type: EXPERIMENTAL
Intervention: golimumab 50 mg
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: golimumab 100 mg
Number of subjects: 308

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 308
Study: 26952220

Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural anesthesia
Number of subjects: 34

Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 34
Study: 24253785

Group type: EXPERIMENTAL
Intervention: Kiva implant with low viscosity PMMA
Number of subjects: 47

Group type: COMPARATOR
Intervention: Balloon kyphoplasty (BK) with high viscosity PMMA
Number of subjects: 47
Study: 22531562

Group type: EXPERIMENTAL
Intervention: Tight glucose control (TGC) implemented in intervention ICUs
Number of subjects: 1321
Study: 20831627

Group type: EXPERIMENTAL
Intervention: Multiple imputation (MI)
Number of subjects: 99
Study: 18587715

Group type: EXPERIMENTAL
Intervention: Supportive treatment including ACE inhibitors, AT1 blockers, statins, dietary counseling, and smoking cessation programs.
Number of subjects: 148

Group type: COMPARATOR
Intervention: Immunosuppressive treatment including steroids or steroids plus cyclophosphamide/azathioprine, in addition to supportive treatment.
Number of subjects: 148
Study: 15752376

Group type: EXPERIMENTAL
Intervention: Clarithromycin 800 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 12187613

Group type: EXPERIMENTAL
Intervention: High-dose chromium picolinate (Cr-pic) supplementation (924 micrograms Cr/d)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Resistive training (RT)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo (low-Cr, < 0.2 microgram Cr/d)
Number of subjects: 17
Study: 10963286

Group type: EXPERIMENTAL
Intervention: 3 doses of recombinant outer-surface protein A (OspA) vaccine administered at 0, 1, and 2 months
Number of subjects: 956

Group type: COMPARATOR
Intervention: 2 doses of recombinant outer-surface protein A (OspA) vaccine administered at 0 and 1 months
Number of subjects: 956
Study: 9202588

Group type: EXPERIMENTAL
Intervention: HASTE MR
Number of subjects: 55

Group type: COMPARATOR
Intervention: CT
Number of subjects: 55

Group type: COMPARATOR
Intervention: IVU
Number of subjects: 55
Study: 1300782

Group type: EXPERIMENTAL
Intervention: Adjuvant hormone therapy in ER+PR+ tumor patients
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Complex therapy
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: PR-positivity
Number of subjects: 271
Study: 3895545

Group type: EXPERIMENTAL
Intervention: Fluoride tablets (FLUDENT) for daily sucking twice a day plus a placebo dentifrice free of fluoride
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: Fluoride dentifrice containing 0.025% F (ACTA)
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: Placebo dentifrice plus fluoride varnish (Duraphat) twice a year
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: Fluoride dentifrice containing 0.025% F (ACTA) plus fluoride varnish (Duraphat) twice a year
Number of subjects: 376
Study: 28694009

Group type: EXPERIMENTAL
Intervention: Dual red imaging (DRI)
Number of subjects: 79

Group type: COMPARATOR
Intervention: White-light imaging (WLI)
Number of subjects: 79
Study: 28059434

Group type: EXPERIMENTAL
Intervention: Tramadol (100 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Buprenorphine (0.6 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (Normal Saline)
Number of subjects: 10
Study: 24217129

Group type: EXPERIMENTAL
Intervention: VRE-DCS (100 mg D-cycloserine administered 90 min before each weekly VRE session)
Number of subjects: 25

Group type: COMPARATOR
Intervention: VRE-placebo (placebo administered 90 min before each weekly VRE session)
Number of subjects: 25
Study: 22878793

Group type: EXPERIMENTAL
Intervention: Warm priming solution at 36 °C
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cold priming solution at 20 °C
Number of subjects: 40
Study: 20484012

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of octreotide (a somatostatin analog)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Physiological saline (control condition)
Number of subjects: 16
Study: 18712481

Group type: EXPERIMENTAL
Intervention: Take Charge of Your Life program (treatment condition)
Number of subjects: 19200

Group type: COMPARATOR
Intervention: Control condition (schools offering drug prevention programming)
Number of subjects: 19200
Study: 15905806

Group type: EXPERIMENTAL
Intervention: Enoxacin 200 mg/d for 11 days
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 12857704

Group type: EXPERIMENTAL
Intervention: Projective bone area (BA) size at the PA lumbar spine
Number of subjects: 1436

Group type: EXPERIMENTAL
Intervention: Projective bone area (BA) size at the lateral lumbar spine
Number of subjects: 1436

Group type: EXPERIMENTAL
Intervention: Detection rates of osteoporosis by aBMD
Number of subjects: 1436
Study: 10858569

Group type: EXPERIMENTAL
Intervention: Intramodality Prior Exposure (IPE) - neutral, non-stressful stimulation in the same modality
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cross-modality Prior Exposure (CPE) - neutral stimuli in a different modality
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stress Only (SO) - a rest period
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low trait anxious subjects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High trait anxious subjects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive stimuli
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Affective stimuli
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-mediational conditions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mediational conditions
Number of subjects: 0
Study: 8891716

Group type: EXPERIMENTAL
Intervention: 1-session condom promotion intervention
Number of subjects: 198

Group type: COMPARATOR
Intervention: Control (stress management) intervention
Number of subjects: 198
Study: 31217488

Group type: EXPERIMENTAL
Intervention: Runs test
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Within test response bias
Number of subjects: 73

Group type: COMPARATOR
Intervention: Forced Choice Test (FCT)
Number of subjects: 73
Study: 29351792

Group type: EXPERIMENTAL
Intervention: Bespoke smoking cessation intervention for people with severe mental ill health
Number of subjects: 526
Study: 27488569

Group type: EXPERIMENTAL
Intervention: LVEF measured by left ventriculography
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: LVEF < 40%
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: LVEF measured by echocardiography
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: LVEF measured within 24 hours
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: LVEF measured not within 24 hours
Number of subjects: 445
Study: 25132340

Group type: EXPERIMENTAL
Intervention: Intradetrusor onabotulinumtoxinA injections
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy subjects (no intervention)
Number of subjects: 0
Study: 22273588

Group type: EXPERIMENTAL
Intervention: Weight loss study intervention at community colleges
Number of subjects: 1004

Group type: EXPERIMENTAL
Intervention: Weight loss study intervention
Number of subjects: 1004
Study: 18682717

Group type: EXPERIMENTAL
Intervention: UFT plus leucovorin (LV) with alternating irinotecan and oxaliplatin
Number of subjects: 45
Study: 16260029

Group type: EXPERIMENTAL
Intervention: Irofulven at 24 mg/m2 every 14 days
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Irofulven at 0.55 mg/kg every 14 days
Number of subjects: 74
Study: 12414079

Group type: EXPERIMENTAL
Intervention: Computer-assisted cognitive rehabilitation (CACR)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Wait-list Control
Number of subjects: 34
Study: 11063636

Group type: EXPERIMENTAL
Intervention: Ifosfamide (1.5 g/m(2)/day for 5 days every 3 weeks for eight courses with mesna uroprotection)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Ifosfamide-cisplatin (ifosfamide with cisplatin 20 mg/m(2)/day for 5 days)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Ifosfamide alone
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Ifosfamide-cisplatin
Number of subjects: 194
Study: 8885752

Group type: EXPERIMENTAL
Intervention: Normal saline solution
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Lactated Ringer's solution plus physiologic glucose
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control (no amnioinfusion)
Number of subjects: 59
Study: 1573338

Group type: EXPERIMENTAL
Intervention: Cyclandelate 1600mg/day
Number of subjects: 61

Group type: COMPARATOR
Intervention: Pizotifen 0.5mg t.i.d.
Number of subjects: 61
Study: 3891347

Group type: EXPERIMENTAL
Intervention: Oral propafenone (600 to 900 mg daily)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oral propafenone (doses exceeding 450 mg day‐1)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oral propafenone
Number of subjects: 12
Study: 30282662

Group type: EXPERIMENTAL
Intervention: Mind-body therapy (MBT) intervention; duration: two days
Number of subjects: 46
Study: 26566681

Group type: EXPERIMENTAL
Intervention: Opium tincture
Number of subjects: 74

Group type: COMPARATOR
Intervention: Methadone syrup
Number of subjects: 74
Study: 24814767

Group type: EXPERIMENTAL
Intervention: Ultrapro mesh (pore size 3-4 mm)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Optilene LP mesh (pore size 1 mm)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 134
Study: 22245620

Group type: EXPERIMENTAL
Intervention: TENS (Transcutaneous Electrical Nerve Stimulation)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 60
Study: 20447037

Group type: EXPERIMENTAL
Intervention: 1-week catheterization
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: 2-week catheterization
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control (1-week catheterization)
Number of subjects: 56
Study: 19098693

Group type: EXPERIMENTAL
Intervention: Non-penetrating needle
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Penetrating needle
Number of subjects: 114
Study: 15986086

Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic field therapy (PEMF) administered using a mat 1.8 x 0.6 m in size, 30 min per session, twice a day for 3 weeks
Number of subjects: 34

Group type: COMPARATOR
Intervention: Sham treatment (placebo group)
Number of subjects: 34
Study: 12839630

Group type: EXPERIMENTAL
Intervention: Ertapenem, 1 g once a day
Number of subjects: 412

Group type: COMPARATOR
Intervention: Piperacillin-tazobactam, 3.375 g every 6 hours
Number of subjects: 412
Study: 10952480

Group type: EXPERIMENTAL
Intervention: Intravenous methylene blue (100 mg)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Oral methylene blue (100 mg)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Intraduodenal methylene blue (in rats)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Methylene blue with mesna (100 mg)
Number of subjects: 7
Study: 9015418

Group type: EXPERIMENTAL
Intervention: Fosinopril (ACE inhibitor), 12 weeks treatment
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Fosinopril
Number of subjects: 34
Study: 1801157

Group type: EXPERIMENTAL
Intervention: Amocarzine (CGP 6140) - a new oral macrofilaricidal compound, administered in three repeat dose regimens.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo control group, consisting of 6 patients.
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ultrasonography using an ophthalmologic real time linear scanner.
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Nodulectomy performed on six nodules around day 10 for initial control purposes.
Number of subjects: 24
Study: 6345161

Group type: EXPERIMENTAL
Intervention: Multifactorial prevention intervention
Number of subjects: 49781
Study: 30829982

Group type: EXPERIMENTAL
Intervention: 10-5-HIIT
Number of subjects: 34

Group type: COMPARATOR
Intervention: 20-10-HIIT
Number of subjects: 34
Study: 29357520

Group type: EXPERIMENTAL
Intervention: Resistance training (eccentric wrist flexion, 3 times/week for 4 weeks)
Number of subjects: 16
Study: 27017071

Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg once daily for 12 weeks
Number of subjects: 1075

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1075
Study: 24998117

Group type: EXPERIMENTAL
Intervention: High flow desflurane anesthesia (Group HF)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Low flow desflurane anesthesia (Group LF)
Number of subjects: 40
Study: 22004181

Group type: EXPERIMENTAL
Intervention: Living with Heart Failure DVD and booklet
Number of subjects: 480

Group type: COMPARATOR
Intervention: Basic written materials only
Number of subjects: 480
Study: 20179530

Group type: EXPERIMENTAL
Intervention: Clinical T staging (T1, T2, T3, T4)
Number of subjects: 1964

Group type: EXPERIMENTAL
Intervention: UICC/AJCC N staging (N0, N1)
Number of subjects: 1964

Group type: EXPERIMENTAL
Intervention: JCGC n staging (n0, n1, n2, n3)
Number of subjects: 1964

Group type: EXPERIMENTAL
Intervention: JCGC n staging within UICC/AJCC N1 category
Number of subjects: 1964
Study: 19005869

Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Multisensorial stimulation (MSS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 15629419

Group type: EXPERIMENTAL
Intervention: Manual acupuncture
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (sham acupuncture with Streitberger needles)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subjective Acupuncture Sensation Scale (SASS)
Number of subjects: 0
Study: 14611917

Group type: EXPERIMENTAL
Intervention: Concomitant chemoradiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sequential platinum-based chemoradiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Advanced radiotherapy techniques, novel chemotherapy combinations, induction chemotherapy, and consolidation chemotherapy with concomitant chemoradiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Molecular therapies integrated with chemoradiotherapy
Number of subjects: 0
Study: 10960397

Group type: EXPERIMENTAL
Intervention: Intraperitoneal meperidine (50 mg) with intraperitoneal bupivacaine (80 mL of 0.125% with 1:200,000 epinephrine)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Intramuscular meperidine (50 mg) with intraperitoneal bupivacaine (80 mL of 0.125% with 1:200,000 epinephrine)
Number of subjects: 100
Study: 8993768

Group type: EXPERIMENTAL
Intervention: TF-B1
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: TF-PBL
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (standard therapy)
Number of subjects: 30
Study: 1535505

Group type: EXPERIMENTAL
Intervention: 200 mg/day 4‐HPR for 5 years
Number of subjects: 3500

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 3500
Study: 6398628

Group type: EXPERIMENTAL
Intervention: Prednisone (2 mg/kg/day for 14 days with tapering and discontinuation by day 21)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 27
Study: 30513377

Group type: EXPERIMENTAL
Intervention: 34 Gy in 1 fraction
Number of subjects: 84

Group type: COMPARATOR
Intervention: 48 Gy in 4 fractions
Number of subjects: 84
Study: 31462466

Group type: EXPERIMENTAL
Intervention: Emotional abilities training programme
Number of subjects: 62

Group type: COMPARATOR
Intervention: Usual educational intervention (Control)
Number of subjects: 62
Study: 28683796

Group type: EXPERIMENTAL
Intervention: Dapagliflozin group (750 mg/day metformin + 5 mg/day dapagliflozin)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Metformin group (1500 mg/day metformin)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Dapagliflozin group
Number of subjects: 80
Study: 25085686

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 µg kg(‐1)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1.0 µg kg(‐1)
Number of subjects: 90
Study: 23751405

Group type: EXPERIMENTAL
Intervention: Percutaneous cystolithotripsy within a laparoscopic entrapment bag and TURP by two surgeons simultaneously
Number of subjects: 76

Group type: COMPARATOR
Intervention: Transurethral cystolithotripsy followed by TURP
Number of subjects: 76
Study: 21316855

Group type: EXPERIMENTAL
Intervention: Pregabalin 150 to 600 mg/day
Number of subjects: 219

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 219
Study: 19595104

Group type: EXPERIMENTAL
Intervention: TACE+HIFU
Number of subjects: 68

Group type: COMPARATOR
Intervention: TACE
Number of subjects: 68
Study: 16573707

Group type: EXPERIMENTAL
Intervention: Phosphodiesterase 5 inhibitors (PDE5-Is)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Selective-serotonin reuptake inhibitors (SSRIs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Behavioural therapy
Number of subjects: 0
Study: 12773645

Group type: EXPERIMENTAL
Intervention: Enfuvirtide (90 mg twice daily) plus optimized background regimen
Number of subjects: 512

Group type: COMPARATOR
Intervention: Control group (optimized background regimen alone)
Number of subjects: 512
Study: 11145490

Group type: EXPERIMENTAL
Intervention: Informed consent process
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Research in emergency situations
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Research associated with risk or discomfort greater than standard treatment
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Information sheets
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Parental involvement in informed consent process
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Clinician agreement on informed consent process
Number of subjects: 200
Study: 9033327

Group type: EXPERIMENTAL
Intervention: High-dose aprotinin
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 42
Study: 8314418

Group type: EXPERIMENTAL
Intervention: Type 1 diabetes patients with CADN
Number of subjects: 1171

Group type: EXPERIMENTAL
Intervention: Type 2 diabetes patients with CADN
Number of subjects: 1171

Group type: EXPERIMENTAL
Intervention: Type 1 diabetes patients with peripheral neuropathy
Number of subjects: 1171

Group type: EXPERIMENTAL
Intervention: Type 2 diabetes patients with peripheral neuropathy
Number of subjects: 1171
Study: 3560028

Group type: EXPERIMENTAL
Intervention: Colon preparation involving wash-out enemas
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Colon preparation involving laxatives
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Colon preparation involving residue-free diet
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Combination of all three methods (residue-free diet, laxatives, wash-out enemas)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Control group (other colon preparations)
Number of subjects: 185
Study: 30160530

Group type: EXPERIMENTAL
Intervention: Integrated yoga (30-min sessions at 30, 32, 34, 36, 37, 38, and 39 weeks of gestation)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Integrated yoga
Number of subjects: 200
Study: 27027541

Group type: EXPERIMENTAL
Intervention: Amphetamine treatment for 3 weeks
Number of subjects: 19
Study: 24772504

Group type: EXPERIMENTAL
Intervention: Improved patient compliance before treatment
Number of subjects: 350

Group type: COMPARATOR
Intervention: Control group (standard treatment without compliance improvement)
Number of subjects: 350
Study: 22535855

Group type: EXPERIMENTAL
Intervention: Text messaging intervention (up to 5 weekly messages)
Number of subjects: 9213

Group type: COMPARATOR
Intervention: Usual care (automated telephone reminder and informational flyers)
Number of subjects: 9213
Study: 20574268

Group type: EXPERIMENTAL
Intervention: Percutaneous adductor longus tenotomy (PAT)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Open adductor longus tenotomy (OAT)
Number of subjects: 27
Study: 19033823

Group type: EXPERIMENTAL
Intervention: Intrabrachial Lys‐[Leu8]‐des‐Arg9‐bradykinin (B1 antagonist)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Lys‐des‐Arg9‐bradykinin (B1 agonist)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Bradykinin (B2 agonist)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (endothelium‐independent vasodilator)
Number of subjects: 16

Group type: COMPARATOR
Intervention: HOE‐140 (B2 antagonist)
Number of subjects: 16
Study: 15988423

Group type: EXPERIMENTAL
Intervention: Racemic albuterol
Number of subjects: 129

Group type: COMPARATOR
Intervention: Levalbuterol
Number of subjects: 129
Study: 12651680

Group type: EXPERIMENTAL
Intervention: Sufentanil (25 microg initial dose, testing interval 1 microg)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Fentanyl (125 microg initial dose, testing interval 5 microg)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Sufentanil/Fentanyl potency ratio
Number of subjects: 66
Study: 9895070

Group type: EXPERIMENTAL
Intervention: TIVA/TCI (propofol-based TCI system and continuous administration of remifentanil)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Isoflurane (inhaled anesthesia with isoflurane, fentanyl, and N2O)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard propofol (fentanyl and N2O with continuous infusion of propofol using a standard delivery system)
Number of subjects: 60